8
Feb
2016
Why Patents Are Sometimes Overrated
You could get the impression, reading about the patent fight over the CRISPR-Cas9 genome editing, that patents are the only thing that matter in biotech. Once the courts sort out who the rightful inventors are, that’s that. The winner gets fame and fortune. Losers get a set of steak knives, or fired. All or nothing. This is a reasonable view... Read More
5
Feb
2016
Are You Ready for Some Football? Maybe Yes, Maybe No
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Feb
2016
As the Smirk Turns, FDA’s Opioid Plan, And A Gene Editing IPO
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Feb
2016
A Short History of Cures for Hepatitis C
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Jan
2016
Merck’s HCV Contender, Red Tickers, and Research Parasites
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Jan
2016
Time to Renew, February Subscribers!
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Jan
2016
Big Pharma May Be a Dinosaur, But It Can Move Fast When It Wants
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Jan
2016
A Clinical Disaster in France, Alkermes Whiffs, and the DMD Anti-Climax
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Jan
2016
Should Basic Lab Experiments Be Blinded to Chip Away at the Reproducibility Problem?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Jan
2016
Post-JPM Perspective, FDA Shoots Down DMD Drug, & Illumina’s Audacity
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Jan
2016
Go-Go Years Have Been Good for Biotech, But Service Providers Are Feeling the Strain
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Jan
2016
Illumina, Arch, Bezos, Gates Bet $100M on Deep Sequencing for Early Cancer Detection
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Jan
2016
All the Biotech Deals and Financings You Can Grok Before JP Morgan 2016
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Jan
2016
Competition Alone Won’t Cut It On Drug Prices
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Dec
2015
Editor’s Picks: The Best of TR from 2015
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Dec
2015
OrbiMed Reloads, Bayer’s CRISPR Foray & Some Good Longreads
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Dec
2015
Which Biotechnologies Were Hyped, and Which Weren’t, in 2015
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Dec
2015
Shkreli Gets Pinched, Cruz Tries to Kneecap FDA & Woodford’s Nutty Investment
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Dec
2015
Why I’m Not Buying Consumer Genetic Tests This Holiday Season
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Dec
2015
Carter’s Immunotherapy Triumph, Wu-Tang Biopharma & A Gut-Brain Startup
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.